CER Daily Newsfeed

Video: Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD

(6/25, Brooke McCormick, Xavier Leleu, MD, PhD, The American Journal of Managed Care) “...The trial found that subcutaneous isatuximab delivered via an on-body delivery system was as effective as the traditional intravenous (IV) form in patients with relapsed/refractory multiple myeloma. It also demonstrated a comparable safety profile, fewer infusion reactions, lower rates of injection site reactions, and greater patient satisfaction.” View Video

ACIP Will ‘Use Evidence-Based Medicine When Making Vaccine Recommendations,’ New Leader Says

(6/25, Richard Payerchin, Medical Economics) reports “...‘ACIP recommendations have an impact on the health and lives of Americans from infancy to old age. Nothing is more precious to those of us on this panel than our children and grandchildren. And likewise, we know they are nothing more important to parents than the health of their children,’ [Chair Martin Kulldorff, MD, PhD] said. ‘Our recommendations cover the lives of over 70 million mostly healthy children,’ he said. ‘Secretary Kennedy has given this committee a clear mandate: to use evidence-based medicine when making vaccine recommendations. And that is what we will do.’” Full

The Data That Heals: How Real-World Data Is Rewriting Healthcare

(6/25, Alex Bedenkov, Forbes.com) comments “...RWE helps identify gaps between clinical guidelines and actual practice. A notable example is a study that used RWD to show that many patients with heart failure were not receiving guideline-directed medical therapy (GDMT). This insight led to targeted interventions aimed at improving adherence to GDMT, ultimately enhancing patient outcomes. Such evidence supports health systems and payers in designing quality improvement programs and value-based care models.” Full

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

(6/25, Neena Brizmohun, Pink Sheet) reports “...The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.” Subscription Required

UK: What Is the Best Treatment for Progressive Vision Loss in People with Diabetes?

(6/25, University of York Centre for Reviews and Dissemination) reports “...To assess the cost-effectiveness of anti-VEGF therapies and whether they represent value for money to the NHS we developed an economic model. We found that anti-VEGF therapies are more expensive than laser surgery, while offering comparable effectiveness. Anti-VEGF therapies are therefore unlikely to be a cost-effective treatment for diabetic retinopathy.” Full

UK: Why NICE Was Right to Say No – for Now – to New Alzheimer’s Drugs

(6/24, Paul Atkinson, Sally Sheard, The Conversation) comments “...Some drug companies have argued that the UK system is flawed, suggesting that even offering their drug for free would not be enough to secure approval. But this misunderstands how Nice works. Evaluating the full cost – not just of the drug, but of scans, infusions and monitoring – is not a flaw, it’s part of responsible decision-making.” Full